

01-22-02

Attorney Docket No.: M0656/7071 (JRV)

21

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications  
under 37 CFR 1.53(b))

Attorney Docket No.

M0656/7071

First Named Inventor or Application Identifier

Ingram et al.

Express Mail Label No.

EL844534283US

Date of Deposit

January 18, 2002

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1. ☐ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.  
☐ Statement filed in prior application, status  
still proper and desired.
3. ☒ Specification -Total pages 52  
45 - pages description  
1- page abstract  
6 - pages claims 48 - Total claims
4. ☒ Drawing(s) (35 USC 113) 11 - Total sheets  
☒ Informal ☐ Formal 11 - Total drawings
5. ☐ Oath or Declaration - Total pages  
a. ☐ Newly executed (original or copy)  
b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)  
[Note Box 6 below]  
i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Incorporation by Reference  
(usable if Box 5b is checked)  
The entire disclosure of the prior application,  
from which a copy of the oath or declaration is  
supplied under Box 5b, is considered as being  
part of the disclosure of the accompanying  
application and is hereby incorporated by  
reference therein. See 19.
7. ☐ Application Data Sheet, See 37 CFR 1.76

## ADDRESS

TO:

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

8. ☐ CD-ROM or CD-R, in duplicate, large table or  
Computer Program (Appendix)
9. ☒ Nucleotide and/or Amino Acid Sequence  
Submission (if applicable, all necessary)
  - a. ☒ Computer Readable Form (CRF)
  - b. ☒ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☒ paper (identical to computer copy)
  - c. ☒ Statement verifying identity of above

## ACCOMPANYING APPLICATION PARTS

10. ☐ Assignment Papers/cover sheet &  
documents(s)
11. ☐ 37 CFR 3.73(b) Statement  
(when there is an assignee)  
☐ Power of Attorney
12. ☐ English Translation of Document (if applicable)
13. ☐ Information Disclosure Statement/PTO-1449  
☐ Copies of IDS Citations
14. ☐ Preliminary Amendment
15. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
16. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
17. ☐ Request and Certification Under 35 U.S.C.  
§122(b)(2)(B)(ii)
18. ☐ Other:

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 09/706,574, filed on November 3, 2000, entitled METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY  $\beta$ -AMYLOID PEPTIDES.

☐ Cancel in this application claims \_\_\_\_\_ before calculating the filing fee.

☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the following:

--This application is a ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.

**Prior application information:** Examiner Unknown Group Art Unit: 1623

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

20. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:



23628

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	
DATE	January 18, 2002

Express Mail Label No. EL844534283US  
Date of Deposit: January 18, 2002

Attorney's Docket No: M0656/7071

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Ingram et al.  
Serial No. : Not assigned  
Filed : Herewith (January 18, 2002)  
For : TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE  
CAUSED BY  $\beta$ -AMYLOID PEPTIDES  
Examiner : Unknown  
Art Unit : Unknown

Box PATENT APPLICATION  
Commissioner for Patents  
Washington, DC 20231

STATEMENT UNDER 37 C.F.R. §1.821(f)

This statement is made pursuant to 37 CFR 1.821(f). Applicant encloses herewith an original written copy of the Sequence Listing and a computer readable diskette. Applicant's attorney states that the information recorded in the computer readable form is identical to the written Sequence Listing and that the Sequence Listing contains no new matter.

Respectfully submitted,

  
John R. Van Amsterdam, Reg No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Tel.: 617-720-3500

DOCKET NO.: M0656/7071  
DATE: January 18, 2002